The eight genes where higher expression was associated with worse prognosis (CYC, CYP51A1, DHFR, EBP, KIF15, PPM1D, SQLE, and UMPS) represent potential additional therapeutic targets in metastatic prostate cancer. Here, CYP51A1 is linked to metastatic prostate carcinoma.